Related Experiment Video

Updated: Oct 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Results of Lipid-Lowering Trials in the Elderly and a Look to the Future

Antonio M. Gotto1

  • 1Department of Medicine, Baylor College of Medicine and the Internal Medicine Service, The Methodist Hospital, Houston, TX.

The American Journal of Geriatric Cardiology
|October 1, 1996
PubMed

Insights

Lipid-lowering therapy may benefit older adults with dyslipidemia, as suggested by studies including elderly participants. Further clinical trials are needed to confirm efficacy in this population.

Area of Science:

  • Gerontology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Clinical research on dyslipidemia treatment in the elderly is limited.
  • Atherogenesis mechanisms are consistent across age groups, suggesting potential applicability of existing data.
  • Existing studies like the Scandinavian Simvastatin Survival Study and West of Scotland Coronary Prevention Study included older populations.

Purpose of the Study:

  • To assess the potential benefits of lipid-lowering therapy in elderly individuals with dyslipidemia.
  • To highlight the need for specific clinical trials in older adults.

Main Methods:

  • Extrapolation of data from clinical trials conducted in middle-aged populations.
  • Analysis of results from secondary and primary prevention trials with significant elderly participant representation.

Main Results:

  • Evidence suggests that lipid-lowering interventions are beneficial for older populations.
  • The Scandinavian Simvastatin Survival Study and West of Scotland Coronary Prevention Study support the efficacy of lipid-lowering in older individuals.

Conclusions:

  • Lipid-lowering therapy shows promise for treating dyslipidemia in the elderly.
  • More dedicated clinical trials are essential to fully establish the efficacy and safety of lipid-regulating treatments in older patients.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...